Teva- Pharmaceutical Industries 

$32.91
625
-$0.78-2.32% Tuesday 20:00

Statistics

Day High
33.7
Day Low
32.8
52W High
37.35
52W Low
14.99
Volume
4,028,909
Avg. Volume
-
Mkt Cap
0
P/E Ratio
25.84
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 17
$0.09
Sep 17
$0.09
Jun 17
$0.34
Mar 17
$0.34
Dec 16
$0.34
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
0.45
0.61
0.77
0.93
Expected EPS
0.60303358872
Actual EPS
N/A

Financials

8.17%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
34.52BRevenue
2.82BNet Income

Analyst Ratings

41.78Average Price Target
The highest estimate is 45.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TEVA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap292.07B
Novartis, through its Sandoz division, is a leading competitor in the generic pharmaceuticals market, directly challenging Teva's product lineup.
Pfizer
PFE
Mkt Cap149.38B
Pfizer, with its Upjohn division now merged into Viatris, competes in both the generic and branded pharmaceutical markets, overlapping with Teva's business areas.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie competes with Teva in the specialty pharmaceutical sector, particularly in areas like biosimilars and branded pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the branded pharmaceutical market, particularly in areas where Teva also operates.
Merck
MRK
Mkt Cap294.03B
Merck competes with Teva in the development and marketing of branded pharmaceuticals, especially in therapeutic areas where Teva is active.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences competes with Teva in the specialty pharmaceuticals market, particularly in the antiviral sector where Teva also has a presence.
AMGEN
AMGN
Mkt Cap191.7B
Amgen competes with Teva in the biopharmaceutical sector, particularly in the development of biosimilars, a growing area of Teva's business.
Sanofi
SNY
Mkt Cap105.92B
Sanofi competes with Teva in both the branded and generic pharmaceutical markets, with a broad product portfolio that overlaps with Teva's.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca competes with Teva in the branded pharmaceutical sector, particularly in areas like respiratory and cardiovascular diseases where Teva is also active.

About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Show more...
CEO
Mr. Richard D. Francis
Employees
37000
Country
United States
ISIN
US8816242098

Listings

0 Comments

Share your thoughts

FAQ

What is Teva- Pharmaceutical Industries stock price today?
The current price of TEVA is $32.91 USD — it has decreased by -2.32% in the past 24 hours. Watch Teva- Pharmaceutical Industries stock price performance more closely on the chart.
What is Teva- Pharmaceutical Industries stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Teva- Pharmaceutical Industries stocks are traded under the ticker TEVA.
Is Teva- Pharmaceutical Industries stock price growing?
TEVA stock has fallen by -2% compared to the previous week, the month change is a -4.02% fall, over the last year Teva- Pharmaceutical Industries has showed a +94.85% increase.
When is the next Teva- Pharmaceutical Industries earnings date?
Teva- Pharmaceutical Industries is going to release the next earnings report on August 05, 2026.
What were Teva- Pharmaceutical Industries earnings last quarter?
TEVA earnings for the last quarter are 0.5 USD per share, whereas the estimation was 0.45 USD resulting in a +10.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Teva- Pharmaceutical Industries revenue for the last year?
Teva- Pharmaceutical Industries revenue for the last year amounts to 34.52B USD.
What is Teva- Pharmaceutical Industries net income for the last year?
TEVA net income for the last year is 2.82B USD.
Does Teva- Pharmaceutical Industries pay dividends?
Yes, TEVA dividends are paid quarterly. The last dividend per share was 0.09 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Teva- Pharmaceutical Industries have?
As of June 17, 2026, the company has 37,000 employees.
In which sector is Teva- Pharmaceutical Industries located?
Teva- Pharmaceutical Industries operates in the Health & Wellness sector.
When did Teva- Pharmaceutical Industries complete a stock split?
The last stock split for Teva- Pharmaceutical Industries was on July 01, 2004 with a ratio of 2:1.
Where is Teva- Pharmaceutical Industries headquartered?
Teva- Pharmaceutical Industries is headquartered in Tel Aviv-Yafo, United States.